Auxly Cannabis wins “Buy” rating from this analyst

Haywood Capital Markets analyst Neal Gilmer initiated coverage of Auxly Cannabis Group (Auxly Cannabis Group Stock Quote, Chart, News, Analysts, Financials TSX:XLY) with a “Buy” rating and $0.25 target in a Dec. 11 report, saying the past year has been “transformative” for the producer as it delivered strong revenue growth and materially strengthened its balance sheet, removing the going-concern uncertainty that had weighed on investor sentiment.

Toronto-based Auxly (best known for its Back Forty brand) operates large-scale cultivation in Leamington, Ont., and a processing and product-development site in Charlottetown, PEI. The portfolio spans major cannabis categories, and the company’s execution in product innovation and quality has lifted it into the country’s top tier of licensed producers.

Gilmer highlighted that Auxly achieved the #3 market share nationally in Q3 2025, with a 6.1% share, and that Back Forty exited the quarter as the #1 cannabis brand in Canada. Auxly also held the #1 non-infused pre-roll brand, the #1 all-in-one vape brand, the #1 flower brand, and ranked as the #3 overall LP.

He emphasized that balance sheet repair has been decisive. The extension of the BMO credit facility and settlement of the Imperial Debenture allowed Auxly to report positive working capital for the first time in 10 quarters.

“In our view, these transactions present a materially stronger balance sheet for investors … and represent an important milestone in management’s ability to execute on strategy,” he said.

Auxly’s financial metrics have also strengthened. Revenue rose 21% in 2024, and Gilmer expects 24.4% growth in 2025, making Auxly “one of the stand-outs in the Canadian cannabis sector.” Gross margin improved to 55.5% in Q3 2025 (from 36.1% in Q1 2024), while SG&A growth remains below the pace of revenue growth, allowing EBITDA margins to expand sharply to 30.8% from 8.9% over the same period.

Gilmer expects Auxly to continue outpacing broader Canadian market growth. Strong gross margins and disciplined cost management should sustain “impressive EBITDA margins and annual cash generation.”

He recommends accumulation at current share levels, arguing that Auxly “has demonstrated the quality of its brands” and that, following debt-reduction progress, the company is positioned to “capture investors’ attention.”

Gilmer forecasts $41.7-million in Adjusted EBITDA on $152.2-million in revenue for fiscal 2025, improving to $45.5-million EBITDA on $163.9-million in revenue in fiscal 2026.

-30-

Tagged with: xly
Nick Waddell

Cantech Letter founder and editor Nick Waddell has lived in five Canadian provinces and is proud of his country's often overlooked contributions to the world of science and technology. Waddell takes a regular shift on the Canadian media circuit, making appearances on CTV, CBC and BNN, and contributing to publications such as Canadian Business and Business Insider.

Recent Posts

Docebo wins huge price target raise at ATB

ATB Capital Markets analyst Gavin Fairweather said after attending Docebo’s (Docebo Stock Quote, Chart, News, Analysts, Financials TSX:DCBO) investor event… [Read More]

6 hours ago

Buy this pot stock for big returns, analyst says

Haywood analyst Neal Gilmer says Organigram Holdings (Organigram Stock Quote, Chart, News, Analysts, Financials TSX:OGI) has established a global cannabis… [Read More]

7 hours ago

iFabric wins “Buy” rating at Beacon Securities

Beacon Securities analyst Doug Cooper initiated coverage of iFabric Corp. (iFabric Stock Quote, Chart, News, Analysts, Financials TSX:IFA) on April… [Read More]

7 hours ago

Investor loves this “undiscovered” aerospace stock

LionGuard Capital Management CEO and CIO Andrey Omelchak told BNN Bloomberg’s Market Call on April 22 that Magellan Aerospace  (Magellan… [Read More]

8 hours ago

This analyst just raised his price target on Cinemark

Roth Capital analyst Eric Handler raised his 12-month price target on Cinemark Holdings (Cinemark Holdings Stock Quote, Chart, News, Analysts,… [Read More]

8 hours ago

WELL Health’s headwinds are in the “rearview mirror”, analyst says

Stifel analyst Justin Keywood said in an April 23 update that management commentary from WELL Health Technologies (WELL Health Technologies… [Read More]

3 days ago